Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy

Sarcoma Clinical Trial

Official title:

Randomized Double-blind Placebo-controlled Trial of Primary Prophylaxis With Recombinant Human Thrombopoietin Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00283582
• Other study ID #: DM00-435
• Status: Completed
• Phase: Phase 3
• Start date: June 2001
• Est. completion date: November 2004

Study information

• Verified date: October 2018
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intensive chemotherapy is often associated with low platelet counts often requiring platelet transfusions to maintain platelet counts. In previous clinical studies administration of rhTPO has been demonstrated to increase platelet counts.

Description:

To evaluate the effectiveness of intravenous rhTPO vs. placebo as primary prophylaxis in reducing the cumulative proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia (platelet count <15,000) during the first four study cycles. To evaluate the severity and duration of thrombocytopenia and neutropenia associated with rhTPO prophylaxis, the impact of rhTPO prophylaxis on health economics/cost effectiveness, and patient quality of life. To assess the safety of multiple IV doses of rhTPO.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: November 2004
• Est. primary completion date: November 2004
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 13 Years and older

Eligibility

Inclusion Criteria:

• Confirmed new diagnosis of moderate or high-grade sarcoma (except leiomyosarcoma of gastrointestinal origin)

• Must have high risk disease by American Joint Committee on Cancer (AJCC) Staging System Stage IIC, III, or IV

• Must have recovered from surgery for a minimum of 2 weeks

• Must be scheduled for a minimum of 4 cycles of AI therapy

• Must be 13 years or older

• Must have ECOG performance status of 0, 1, or 2.

• Must have life expectancy of at least 12 weeks.

• Left ventricular ejection fraction must be more than 50%.

• Laboratory data within normal limits.

Exclusion Criteria:

• Prior front-line standard or experimental therapy for sarcoma

• History of bone marrow and or peripheral blood progenitor cell transplantation

• Prior pelvic radiation or radiation therapy to more than 25% of bone marrow reserves

• Prior treatment with megakaryocyte growth and differentiation factor

• Prior treatment with rhTPO

• History of platelet disorder

• History of myocardial infarction, stroke, pulmonary embolism, or deep vein thrombosis within the past 12 months

• Pregnant or lactating women

• Use of anticoagulants such as coumadin, heparin, etc.

• Known HIV or hepatitis

Related Conditions & MeSH terms

• Sarcoma

Intervention

Drug:
• rhTPO

Locations

Country	Name	City	State
United States	UT MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CBC with diff. at least three times a week and daily if platelet less than 50,000. Chemistry, coagulation, urinalysis performed at baseline and at end of cycle if necessary.

External Links

•   UT MD Anderson Cancer Center Website